Physician profile
John I Jarad
NPI 1245235654
$3,193.95
in general payments reported to CMS, 2019-2025
39 companies · $420 in 2025
The $420 reported for 2025 was more than what 76% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $884 · 2021: $127 · 2022: $62.71 · 2023: $307 · 2024: $329 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $292.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $267.60 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $232.58 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $180.46 | 2020-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $143.32 | 2019-2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $136.68 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $135.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $132.31 | 2019-2023 | |
| Glaxosmithkline, LLC. | $125.96 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $124.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $107.66 | 2019-2021 | |
| Edwards Lifesciences Corporation | $90.86 | 2020 | |
| Abbvie INC. | $83.38 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $66.10 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jarad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.